Delivery Order SPE2DB22D2009-SPE2DB25FM1SM
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Tezspire 210 mg/1.91 mL pen auto-injectors. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $7,030.77 and is scheduled for completion by September 12, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a single transaction within...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,343.59 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 ml pen auto-injectors. This firm fixed-price, non-set-aside contract was executed on September 23, 2025, with an ultimate completion date of October 15, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Tezspire 210 mg/1.91 mL pen auto-injectors, valued at $2,343.59 with a firm fixed price structure. This is a non-set-aside, competitively awarded contract with an ultimate completion date of September 16, 2025. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a standard pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,374.36 to AmerisourceBergen Drug Corp on July 11, 2025, for the supply of TEZSPIRE 210 mg/1.91 mL auto-injector pens. This firm fixed-price delivery order, which is not associated with any set-aside program, will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of August 1, 2025. The award represents a routine pharmaceutical procurement under the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors valued at $4,687.18, with completion targeted for September 29, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a single transaction under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $9,374.36 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 ml pen auto-injectors, with an ultimate completion date of August 22, 2025. This non-set-aside, competitively awarded contract represents a firm fixed price delivery order for pharmaceutical products to support federal medical supply needs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors, with a ceiling value of $4,687.18 and an ultimate completion date of September 29, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's corporate headquarters in Conshohocken, Pennsylvania. The contract represents a routine...
- AmerisourceBergen Drug Corp has been awarded a delivery order by the Defense Logistics Agency (DLA) for $2,343.59 to supply Tezspire 210 mg/1.91 mL pen injectors, with an ultimate completion date of October 10, 2025. This non-competitive, firm fixed-price delivery order was issued on September 19, 2025, and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement supporting federal medical supply...
- The Defense Logistics Agency awarded a $9,374.36 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL pen auto-injectors on July 16, 2025, with completion by August 6, 2025. This non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The product will be delivered to AmerisourceBergen's facility in...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a competitive delivery order valued at $9,374.36 on August 18, 2025, with completion scheduled for September 9, 2025. The contract covers the supply of Tezspire 210 mg/1.91 mL pen auto-injectors and was funded through the Defense Logistics Agency's Medical Supply Chain division. This firm fixed-price delivery order represents a non-set-aside award, indicating open...
- SPE2DB22D2009Indefinite Delivery Contract
- SPE2DB22D2009-SPE2DB25FM1SMDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Tezspire 210 mg/1.91 ml pen auto-injectors. The contract is valued at $2,343.59 with a firm fixed price structure and is scheduled for completion by October 20, 2025. This competitively awarded order carries no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. As a major pharmaceutical distributor, AmerisourceBergen serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the DLA's Medical Supply Chain. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. This comprehensive prime vendor contract enables the company to supply a broad range of pharmaceutical products and medical commodities globally to support military healthcare programs. The contract arrangement reflects the DLA's strategy to maintain reliable pharmaceutical supply chains for the Defense Health Agency and other federal healthcare systems through established vendor relationships with proven capability to meet federal procurement requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 9/26/25 |